A Phase 1 Trial of Amplimexon (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma

Trial Profile

A Phase 1 Trial of Amplimexon (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2010

At a glance

  • Drugs Gemcitabine; Imexon
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AmpliMed
  • Most Recent Events

    • 09 Feb 2010 Actual patient numbers amended from 96 to 105 as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top